Evaluating clinical trial designs for investigational treatments of Ebola virus disease
about
Critical role of ethics in clinical management and public health response to the West Africa Ebola epidemicMathematical modeling of the West Africa Ebola epidemicTransforming Clinical Data into Actionable Prognosis Models: Machine-Learning Framework and Field-Deployable App to Predict Outcome of Ebola PatientsTreating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.Modernising epidemic science: enabling patient-centred research during epidemicsDesign of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM StudyExperimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in GuineaExperimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial"Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials?Offering patients more: how the West Africa Ebola outbreak can shape innovation in therapeutic research for emerging and epidemic infectionsA response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic responseExperimental Therapies for Ebola Virus Disease: What Have We Learned?GOST: A generic ordinal sequential trial design for a treatment trial in an emerging pandemic.Experimental Treatment of Ebola Virus Disease with Brincidofovir.A Systematic Review of Ebola Treatment Trials to Assess the Extent to Which They Adhere to Ethical Guidelines.Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material.Statistical considerations for a trial of Ebola virus disease therapeutics.Trial design for evaluating novel treatments during an outbreak of an infectious disease.Improving vaccine trials in infectious disease emergencies.The Ebola clinical trials: a precedent for research ethics in disasters.[Science in a crisis. Medical countermeasures in Ebola virus disease, 2016: lessons learned and perspectives].A US Food and Drug Administration perspective on evaluating medical products for Ebola.A viewpoint on European Medicines Agency experience with investigational medicinal products for Ebola.Ebola clinical trials: Five lessons learned and a way forward.Displacement of sexual partnerships in trials of sexual behavior interventions: A model-based assessment of consequences.Drug assessment in the Ebola virus disease epidemic in west Africa.Simulations for designing and interpreting intervention trials in infectious diseases.A comparison of the barely Bayesian design with the triangular test for clinical trials in infectious diseases.Performance of different clinical trial designs to evaluate treatments during an epidemic
P2860
Q24658595-CE534638-9FB0-4709-AE12-5211C955C2B9Q24696016-5612AEF9-8A38-4A92-89C9-E46237F8BEB7Q27077202-A686395A-2796-46C6-A800-5F3E73272616Q28076034-D3479613-E064-4D0D-9862-9D53B9036ABFQ28119742-088FD5BB-0308-4FF6-898A-8CBA15ACC87EQ28395071-844CF97F-01C7-4819-82D8-6206638767A3Q28550455-54211E35-6078-462C-A4BC-942B92F858DCQ28551448-C5F3F988-EC3F-4F86-9A13-B9CFE76EA317Q28595570-AAE33DBE-3934-40DB-B630-1D3261C96CF2Q29994672-19AA31B3-148A-4271-AC61-96324693D4B4Q30196960-CD791CC3-DB03-40F6-AACF-582129C580F7Q30275032-D9282DC8-CA02-421F-B9E0-8B8739364D52Q30399706-227C6EA5-494B-45A4-B18E-3E5E06EF24BCQ36127815-7C862724-EEE0-4332-9E4A-30F3AE8FA38BQ36251369-AA118A26-1433-4E61-A830-79BB0299FAFAQ36403500-FAB32268-35B5-46AD-8CD1-C12A572AAD1BQ36620043-42A6C07E-1F5C-47BB-9B54-445D49EC2B71Q38920677-09EB5BEB-1F94-4890-A9AD-D46D677CD3CBQ39433750-DA59F184-5B67-455F-B0F8-9353BDFEB8D4Q39442554-AE1FAE7B-1DF7-4D2C-94D6-C34EDBD84238Q40079929-DE967DBA-907D-4809-B111-F5178D16D1E5Q40122769-95095860-9CC6-448C-BB7F-5BACF9265ACDQ40122789-DAE8BD14-82CD-40E4-B7F9-D34D4820AE88Q40122803-DEF0859E-5575-4933-B745-FD96BCE43F48Q40239707-B3C24A80-49B9-4AB8-BB3E-6A1CBF7404D6Q44100737-A32C7104-ABC1-418D-B821-1D6B08819EDEQ47106919-8844A7D9-29ED-420C-A9F9-34B7E1A30A6AQ53775146-38D8F2DE-FD25-4BA0-927B-73C0174A82CAQ57091968-5F08FFCD-74B0-4FCC-869F-CD3F6973CFB5
P2860
Evaluating clinical trial designs for investigational treatments of Ebola virus disease
description
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
article scientifique
@fr
artículu científicu espublizáu en 2015
@ast
scientific article (publication date: April 2015)
@en
vedecký článok (publikovaný 2015-04)
@sk
vědecký článek publikovaný v roce 2015
@cs
wetenschappelijk artikel (gepubliceerd in 2015-04)
@nl
wissenschaftlicher Artikel
@de
наукова стаття, опублікована у квітні 2015
@uk
name
Evaluating clinical trial designs for investigational treatments of Ebola virus disease
@ast
Evaluating clinical trial designs for investigational treatments of Ebola virus disease
@en
Evaluating clinical trial designs for investigational treatments of Ebola virus disease
@nl
type
label
Evaluating clinical trial designs for investigational treatments of Ebola virus disease
@ast
Evaluating clinical trial designs for investigational treatments of Ebola virus disease
@en
Evaluating clinical trial designs for investigational treatments of Ebola virus disease
@nl
prefLabel
Evaluating clinical trial designs for investigational treatments of Ebola virus disease
@ast
Evaluating clinical trial designs for investigational treatments of Ebola virus disease
@en
Evaluating clinical trial designs for investigational treatments of Ebola virus disease
@nl
P2093
P2860
P50
P3181
P1433
P1476
Evaluating clinical trial designs for investigational treatments of Ebola virus disease
@en
P2093
John Whitehead
Maciej F Boni
Wirichada Pan-ngum
P2860
P304
P3181
P356
10.1371/JOURNAL.PMED.1001815
P407
P50
P577
2015-04-01T00:00:00Z